Adagene Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

AdageneDer Gewinn des Unternehmens wird voraussichtlich um 8.1% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 23.4% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich um 3.8% pro Jahr wachsen.

Wichtige Informationen

-8.1%

Wachstumsrate der Gewinne

3.8%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.5%
Wachstumsrate der Einnahmen	23.4%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	08 Apr 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Adagene Inc. (NASDAQ:ADAG) Surges 26% Yet Its Low P/S Is No Reason For Excitement

Oct 10

The Consensus EPS Estimates For Adagene Inc. (NASDAQ:ADAG) Just Fell Dramatically

Oct 05

Adagene ADR GAAP EPS of -$0.87 misses by $0.45, revenue of $3.93M misses by $9.82M

Aug 30

Micro-cap Adagene surges after hours on $10M share buyback

Jun 29

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:ADAG - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	20	-110	N/A	N/A	2
12/31/2025	N/A	-92	N/A	N/A	1
12/31/2024	N/A	-49	N/A	N/A	1
12/31/2023	18	-19	-29	-28	N/A
9/30/2023	20	-28	N/A	N/A	N/A
6/30/2023	23	-36	N/A	N/A	N/A
3/31/2023	16	-58	N/A	N/A	N/A
12/31/2022	9	-80	-49	-49	N/A
9/30/2022	11	-82	N/A	N/A	N/A
6/30/2022	13	-84	N/A	N/A	N/A
3/31/2022	11	-78	N/A	N/A	N/A
12/31/2021	10	-73	-46	-43	N/A
9/30/2021	6	-68	N/A	N/A	N/A
6/30/2021	2	-62	N/A	N/A	N/A
3/31/2021	1	-52	N/A	N/A	N/A
12/31/2020	1	-43	-29	-29	N/A
9/30/2020	1	-34	-27	-26	N/A
6/30/2020	1	-28	-21	-21	N/A
3/31/2020	1	-22	-20	-20	N/A
12/31/2019	0	-17	-18	-18	N/A
12/31/2018	2	-14	-15	-14	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ADAG wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: ADAG wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: ADAG wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: ADAG wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: ADAG wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von ADAG in 3 Jahren voraussichtlich hoch sein wird

Adagene Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 32% to US$9.16

Price target decreased by 9.4% to US$12.53

Price target increased to US$13.82

Price target decreased to US$10.78

Price target decreased to US$12.71

Consensus forecasts updated

Recent updates

New minor risk - Market cap size

New major risk - Revenue and earnings growth

Full year 2023 earnings released: US$1.83 loss per share (vs US$1.85 loss in FY 2022)

Adagene Inc. Announces Board Changes

New minor risk - Financial data availability

Adagene Inc. Appoints Heinz-Josef Lenz to Scientific and Strategic Advisory Board

Adagene Inc. Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody

New major risk - Share price stability

Adagene Inc. Announces Data from its Presentation at the American Society of Clinical Oncology 2024 Gastrointestinal (GI) Cancers Symposium

Adagene Inc. Presents Data Demonstrating the Best-In-Class Therapeutic Index for Masked Anti-CTLA-4 Safebody®? Adg126

Adagene Inc. (NASDAQ:ADAG) Surges 26% Yet Its Low P/S Is No Reason For Excitement

New major risk - Revenue and earnings growth

Price target decreased by 32% to US$9.16

Full year 2022 earnings released: US$1.85 loss per share (vs US$1.83 loss in FY 2021)

Price target decreased by 9.4% to US$12.53

Adagene Announces Interim Data Demonstrating Safety and Confirmed Clinical Responses of Anti-Ctla-4 Safebody® Adg126 Up to 10 Mg/Kg with Repeat Cycles in Combination with Anti-Pd-1 Therapy from Dose Escalation Portion of Phase 1B/2 Trial

Price target increased to US$13.82

Price target decreased to US$10.78

Adagene Inc. Appoints Cuong Do to Board of Directors and Audit Committee

Price target decreased to US$12.71

High number of new and inexperienced directors

Adagene Announces Clinical Data at SITC 2022 on Anti-CTLA-4 NEObody™, ADG116, Showing Differentiated Safety and Anti-tumor Activity in Heavily Pre-treated Patients with Difficult-to-Treat Tumors

The Consensus EPS Estimates For Adagene Inc. (NASDAQ:ADAG) Just Fell Dramatically

Consensus forecasts updated

Adagene Inc. Presents Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-Tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody® ADG126 in Patients with Advanced Tumors

Price target increased to US$27.92

First half 2022 earnings released: US$1.09 loss per share (vs US$1.02 loss in 1H 2021)

Adagene ADR GAAP EPS of -$0.87 misses by $0.45, revenue of $3.93M misses by $9.82M

Adagene Inc. (NasdaqGM:ADAG) announces an Equity Buyback for $10 million worth of its shares.

Micro-cap Adagene surges after hours on $10M share buyback

Adagene Announces Publication at ASCO of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of Anti-CTLA-4 SAFEbody ADG126, with Repeat Dosing Across Dose Levels

High number of new and inexperienced directors

Adagene Inc. Presents Data Demonstrating First and Best-In-Class Potential for Differentiated Preclinical Antibody Candidates At American Association for Cancer Research (Aacr) Annual Meeting 2022

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$25.69

Adagene Inc. Announces Board and Management Changes

Adagene Announces First Patient Dosed with Novel, Proprietary Combination of Anti-CD137 Agonist, ADG106, and Anti-CTLA-4 Monoclonal Antibody, ADG116

Adagene Inc. Announces First Patients with Advanced Non-Small Cell Lung Cancer Dosed in Phase 1B/2 Clinical Trial of ADG106 in Combination with Nivolumab in Singapore

Adagene Announces FDA Clearance of IND for Phase 1b/2 Trial of Anti-CTLA-4 Monoclonal Antibody ADG116 in Combination Therapy with Anti-PD-1 Antibody Pembrolizumab

Director Yu Miao has left the company

Adagene Inc. Announces Clinical Data from its ADG106 NEObodyTM Program

Adagene Inc. Announces First Patients Dosed in Global Phase 1 Clinical Trial of ADG126 for the Treatment of Various Advanced Solid Tumors

Adagene Inc. has completed an IPO in the amount of $139.726 million.

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken